D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.

History

History

1999 Feb. aimed to develop new drugs, established D. Western Therapeutics Institute, Inc. as a private company in Showa-ku Nagoya City.
2002 Sep. contracted for development and implementation of anti-platelet drug (K-134) and anti-glaucoma drug (K-115) with Kowa Co., Ltd.
2004 Jul. initiated phase I trial for anti-platelet drug (K-134) in Europe.
Nov. converted to a joint-stock corporation. (10 million yen in capital)
2005 Apr. completed phase I trial for anti-platelet drug (K-134) in Europe.
Dec. moved head office to Naka-ku Nagoya City.
2006 Apr. initiated phase I trial for anti-platelet drug (K-134) in Japan.
Jul. initiated phase I trial for anti-glaucoma drug (K-115) in Japan.
successfully identified target protein of anti-platelet drug (K-134)
Dec. established Institute of Human Research Promotion and Drug Development at Mie University Faculty of Medicine under collaborative research agreement.
2007 Oct. completed phase I trial for anti-platelet drug (K-134) in Japan.
completed phase I trial for anti-glaucoma drug (K-115) in Japan.
2008 Jul. initiated phase IIa trial for anti-platelet drug (K-134) in Japan.
Dec. initiated phase IIa trial for anti-platelet drug (K-134) in U.S.
2009 Mar. initiated phase II trial for anti-glaucoma drug (K-115) in Japan.
Oct. listed on Tokyo Securities Exchange JASDAQ(Growth).
2011 Jan. completed phase IIa trial for anti-platelet drug (K-134) in U.S.
completed phase II trial for anti-glaucoma drug (K-115) in Japan.
Jun. completed phase IIa trial for anti-platelet drug (K-134) in Japan.
Sep. initiated phase III trial for anti-glaucoma drug (K-115) in Japan.
2012 Jan. initiated phase IIb trial for anti-platelet drug (K-134) in Japan.
2013 Mar. contracted for exclusive license and sublicense of development, production, and sales for anti-glaucoma drug (WP-1303[H-1129]) with Wakamoto Pharmaceutical Co., Ltd. in Japan.
Apr. completed phase III trial for anti-glaucoma drug (K-115) in Japan.
Oct. filed NDA application for anti-glaucoma drug (K-115) in Japan. (indication of glaucoma & ocular hypertension)
Dec. initiated non-clinical studies for anti-glaucoma drug (WP-1303[H-1129]).
2014 Sep. acquired Marketing Approval for glaucoma & ocular hypertension treatment drug (GLANATEC® ophthalmic solution 0.4% / K-115) in Japan.
Dec. launched for glaucoma & ocular hypertension treatment drug (GLANATEC® ophthalmic solution 0.4% / K-115) in Japan.
completed phase IIb trial for anti-platelet drug (K-134) in Japan.
2015 Jun. acquired exclusive license and sublicense of development, production and sales for ophthalmic analgesic in Japan.
Nov. Japan Innovative Therapeutics, Inc. became consolidated subsidiary company.
2016 Mar. initiated phase I trial for glaucoma treatment drug (WP-1303 [H-1129]) in Japan.
Apr. initiated non-clinical studies for glaucoma treatment drug (H-1337).
2017 Mar. completed phase I trial for glaucoma treatment drug (WP-1303 [H-1129]) in Japan.
Aug. initiated phase II trial for glaucoma treatment drug (WP-1303 [H-1129]) in Japan.
Dec. filed Marketing Approval for glaucoma & ocular hypertension treatment drug (GLANATEC® ophthalmic solution 0.4% / K-115) in Korea.(indication of glaucoma & ocular hypertension)

As of December 2017

PAGETOP
D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.